![]() |
市場調查報告書
商品編碼
2176438
人工智慧驅動的多模態醫療診斷市場預測至2034年-全球分析(按診斷模式、解決方案組件、臨床應用、人工智慧技術、最終用戶和地區分類)AI-Powered Multimodal Medical Diagnostics Market Forecasts to 2034 - Global Analysis By Diagnostic Modality, Solution Component, Clinical Application, AI Technology, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球人工智慧驅動的多模態醫療診斷市場預計將在 2026 年達到 32 億美元,並在預測期內以 17.2% 的複合年成長率成長,到 2034 年達到 113 億美元。
人工智慧驅動的多模態醫學診斷利用先進的人工智慧技術,整合醫學影像、病理學、基因組資訊、檢測結果、生理訊號和臨床記錄,以支援疾病檢測和診斷決策。慢性病盛行率的不斷上升、精準醫療需求的成長以及醫療數據量的激增,正在推動市場發展。多模態平台模型、深度學習和臨床資料融合技術的進步,正在提升診斷能力。對人工智慧驅動的醫療基礎設施、個人化診斷和整合臨床決策支援的投資不斷增加,正在為全球創造巨大的商機。
準確診斷和整合各種臨床數據的需求日益成長。
精準診斷和整合多樣化臨床數據的需求日益成長,正在推動市場擴張。醫療機構正在產生大量數據,包括醫學影像、實驗室結果、病理學觀察、基因組資訊和電子健康記錄。多模態人工智慧平台整合這些資料來源,以支援更全面的疾病評估和臨床決策。慢性病盛行率的上升、診斷工作量的增加以及人們對個人化醫療日益成長的興趣,都在推動其應用。醫療數據互通性和人工智慧驅動的解讀技術的進步,進一步提升了醫療機構對整合診斷解決方案的需求。
臨床資料互通性的挑戰以及實施多模態人工智慧的高成本。
臨床數據互通性的挑戰以及實施多模態人工智慧的高成本正在阻礙市場成長。醫學影像、病理、基因組學和臨床記錄通常在使用不同資料格式和標準的獨立資訊系統中運作。整合這些資料集需要複雜的整合基礎設施、廣泛的資料協調以及大量的運算資源。高品質、帶註釋的多模態資料集的匱乏也增加了演算法開發和檢驗的難度。醫療機構也面臨監管合規、資料隱私和工作流程整合等挑戰。高昂的實施成本可能限制小規模醫療機構的採用。
多模態基礎設施模型和精準醫療診斷平台的擴展
多模態基礎模型和精準醫療診斷平台的擴展帶來了巨大的成長機會。先進的人工智慧模型能夠整合並分析影像、病理、基因組圖譜和臨床病史,從而識別複雜的疾病模式並支援個人化治療決策。對腫瘤診斷、生物標記發現和分子譜分析領域投資的不斷增加正在推動這些技術的應用。醫療科技公司、診斷實驗室和研究機構之間的合作正在促進其商業化。數據融合、可解釋人工智慧和臨床檢驗的進步有望將多模態診斷應用擴展到多個疾病領域。
演算法偏見、對診斷可靠性的擔憂以及不斷變化的醫療人工智慧監管法規
演算法偏差、對診斷可靠性的擔憂以及不斷變化的醫療人工智慧監管法規都對市場擴張構成威脅。如果多模態診斷系統使用不完整、缺乏代表性或不一致的臨床資料集進行訓練,則可能產生不準確的預測。患者群體、影像方案和檢查程序的差異會影響模型的泛化能力。醫療服務提供者面臨病患安全問題、法律責任風險以及人工智慧輔助診斷的監管。網路安全威脅和對敏感健康資料的要求進一步增加了部署的複雜性。技術開發商必須證明其臨床有效性、透明度、健全的數據管治以及有效的臨床醫生監督,才能維持市場信心。
新冠疫情加速了醫療數位化進程,並提升了人們對人工智慧診斷技術的興趣。診斷工作的繁重、遠端臨床評估的需求以及醫學影像的廣泛應用,都促使人們增加對自動化分析和數據整合的投資。然而,臨床研究、醫療設備供應鏈以及醫院預算的中斷,導致一些計畫實施進程延誤。疫情也凸顯了整合影像、實驗室和臨床資訊進行疾病評估的重要性。因此,對醫療人工智慧、數位病理學和整合診斷的投資,正推動多模態診斷平台的持續發展。
在預測期內,醫療影像和臨床資料區段預計將佔據最大的市場佔有率。
在預測期內,醫學影像和臨床資料區段預計將佔據最大的市場佔有率,這主要得益於診斷影像和電子健康記錄在醫療服務中的廣泛應用。將放射影像與病患病歷、實驗室觀察和臨床觀察結合,能夠實現更具情境性的診斷評估。完善的影像基礎設施和日益普及的數位化臨床記錄正在推動這一領域的應用。人工智慧放射學、臨床決策支援和整合診斷工作流程的日益普及進一步增強了市場需求。影像解讀、自然語言處理和資料互通性的進步也進一步鞏固了該領域的市場地位。
預計在預測期內,多模態基礎模型細分市場將呈現最高的複合年成長率。
在預測期內,由於對能夠在統一系統中解讀多種醫療資料類型的AI架構的投資不斷增加,多模態基礎模型領域預計將呈現最高的成長率。這些模型能夠整合影像、臨床文字、分子資訊和結構化醫療記錄,從而支持診斷推理和疾病預測。自監督學習、大規模預訓練和領域自適應技術的進步正在提升這些模型的能力。醫療機構與AI開發者之間日益密切的合作正在推動商業化進程。對擴充性、可適應且整體性的診斷智慧的需求預計將加速該領域的成長。
在預測期內,北美預計將佔據最大的市場佔有率,這主要得益於其先進的醫療基礎設施、對人工智慧的大量投資以及數位診斷技術的廣泛應用。美國正透過醫療科技公司、研究機構、診斷檢測實驗室和醫療網路對人工智慧驅動的診斷技術的投資,推動區域發展。對精準醫療、腫瘤檢測和綜合臨床分析日益成長的需求,正在推動這些技術的應用。技術提供者與醫療機構之間合作的不斷深化,進一步鞏固了該地區的市場領導地位。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療基礎設施的持續改善、診斷需求的成長以及人工智慧領域投資的增加。中國、印度、日本、韓國和澳洲正在推動數位醫療系統、醫學影像技術和精準醫療的進步。龐大的患者群體和慢性病盛行率的上升正在推動高度擴充性的診斷解決方案的應用。對醫療技術的投資增加、基因組檢測能力的提升以及政府主導的數位健康項目,都為該地區的成長提供了支持。
According to Stratistics MRC, the Global AI-Powered Multimodal Medical Diagnostics Market is accounted for $3.2 billion in 2026 and is expected to reach $11.3 billion by 2034 growing at a CAGR of 17.2% during the forecast period. AI-Powered Multimodal Medical Diagnostics involves the integration of medical imaging, pathology, genomic information, laboratory results, physiological signals, and clinical records through advanced artificial intelligence technologies to support disease detection and diagnostic decision-making. Increasing prevalence of chronic diseases, growing demand for precision medicine, and expanding healthcare data volumes are driving market development. Technological advancements in multimodal foundation models, deep learning, and clinical data fusion are improving diagnostic capabilities. Growing investments in AI-enabled healthcare infrastructure, personalized diagnostics, and integrated clinical decision support are creating significant opportunities worldwide.
Increasing demand for accurate diagnostics and integration of diverse clinical data
Increasing demand for accurate diagnostics and integration of diverse clinical data is driving market expansion. Healthcare providers generate substantial volumes of medical imaging, laboratory results, pathology findings, genomic information, and electronic health records. Multimodal AI platforms combine these data sources to support more comprehensive disease assessment and clinical decision-making. Rising chronic disease prevalence, growing diagnostic workloads, and increasing interest in personalized medicine encourage adoption. Advancements in medical data interoperability and AI-assisted interpretation further strengthen demand for integrated diagnostic solutions across healthcare institutions.
Clinical data interoperability challenges and high costs of multimodal AI implementation
Clinical data interoperability challenges and high costs of multimodal AI implementation restrain market growth. Medical imaging, pathology, genomics, and clinical records frequently operate within separate information systems using different data formats and standards. Combining these datasets requires sophisticated integration infrastructure, extensive data harmonization, and substantial computational resources. Limited availability of high-quality annotated multimodal datasets complicates algorithm development and validation. Healthcare organizations also face regulatory compliance, data privacy, and workflow integration challenges. High implementation expenses may restrict adoption among smaller healthcare providers.
Expansion of multimodal foundation models and precision medicine diagnostic platforms
Expansion of multimodal foundation models and precision medicine diagnostic platforms presents significant growth opportunities. Advanced AI models can jointly analyze imaging, pathology, genomic profiles, and clinical histories to identify complex disease patterns and support individualized treatment decisions. Increasing investment in oncology diagnostics, biomarker discovery, and molecular profiling encourages adoption. Partnerships between healthcare technology companies, diagnostic laboratories, and research institutions support commercialization. Improvements in data fusion, explainable AI, and clinical validation are expected to expand multimodal diagnostic applications across multiple disease areas.
Algorithmic bias, diagnostic reliability concerns, and evolving medical AI regulations
Algorithmic bias, diagnostic reliability concerns, and evolving medical AI regulations threaten market expansion. Multimodal diagnostic systems may produce inaccurate predictions when trained on incomplete, unrepresentative, or inconsistent clinical datasets. Differences in patient populations, imaging protocols, and laboratory procedures can affect model generalizability. Healthcare providers face patient safety concerns, liability exposure, and regulatory scrutiny regarding AI-assisted diagnoses. Cybersecurity threats and sensitive health data requirements further complicate deployment. Technology developers must demonstrate clinical validity, transparency, robust data governance, and effective clinician oversight to maintain market confidence.
The COVID-19 pandemic accelerated healthcare digitalization and increased interest in AI-assisted diagnostic technologies. High diagnostic workloads, demand for remote clinical assessment, and increased medical imaging utilization encouraged investment in automated analysis and data integration. However, disruptions to clinical research, equipment supply chains, and hospital budgets delayed certain implementation projects. The pandemic also highlighted the importance of combining imaging, laboratory testing, and clinical information for disease assessment. Subsequent investment in healthcare AI, digital pathology, and integrated diagnostics has supported continued development of multimodal diagnostic platforms.
The medical imaging & clinical data segment is expected to be the largest during the forecast period
The medical imaging & clinical data segment is expected to account for the largest market share during the forecast period due to widespread utilization of diagnostic imaging and electronic health records in healthcare delivery. Combining radiological images with patient histories, laboratory findings, and clinical observations enables more contextual diagnostic assessments. Established imaging infrastructure and increasing availability of digital clinical records support implementation. Growing adoption of AI-assisted radiology, clinical decision support, and integrated diagnostic workflows strengthens demand. Advances in image interpretation, natural language processing, and data interoperability further reinforce the segment's market position.
The multimodal foundation models segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the multimodal foundation models segment is predicted to witness the highest growth rate due to increasing investment in AI architectures capable of interpreting diverse medical data types within unified systems. These models can integrate images, clinical text, molecular information, and structured health records to support diagnostic reasoning and disease prediction. Advances in self-supervised learning, large-scale pretraining, and domain adaptation are improving model capabilities. Growing collaboration between healthcare institutions and AI developers supports commercialization. Demand for scalable, adaptable, and comprehensive diagnostic intelligence is expected to accelerate segment growth.
During the forecast period, the North America is expected to hold the largest market share due to advanced healthcare infrastructure, substantial investment in artificial intelligence, and widespread adoption of digital diagnostic technologies. The United States leads regional development through medical technology companies, research institutions, diagnostic laboratories, and healthcare networks investing in AI-enabled diagnostics. Growing demand for precision medicine, oncology testing, and integrated clinical analytics encourages adoption. Increasing collaboration between technology providers and healthcare organizations further strengthens regional market leadership.
Over the forecast period, the Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, rising diagnostic demand, and increasing investment in artificial intelligence. China, India, Japan, South Korea, and Australia are advancing digital healthcare systems, medical imaging technologies, and precision medicine initiatives. Large patient populations and increasing chronic disease prevalence encourage adoption of scalable diagnostic solutions. Growing healthcare technology investment, expanding genomic testing capabilities, and government digital health programs support regional development.
Key players in the market
Some of the key players in the AI-Powered Multimodal Medical Diagnostics Market include Tempus AI, Inc., SOPHiA GENETICS SA, Owkin, Inc., PathAI, Inc., Aidoc Medical Ltd., Qure.ai, Lunit, Inc., Ibex Medical Analytics Ltd., Caris Life Sciences, Inc., Foundation Medicine, Inc., Quibim S.L., Viz.ai, Inc., HeartFlow, Inc., GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Roche Holding AG, and Thermo Fisher Scientific Inc.
In September 2026, Tempus AI, Inc. announced an initiative to develop a large-scale multimodal whole-genome dataset integrating genomic sequences with longitudinal clinical outcomes. The initial objective is to assemble 100,000 disease-specific whole-genome sequences, with a longer-term ambition of reaching one million genomes.
In August 2026, Tempus AI, Inc. announced results from a study published in Nature Medicine evaluating PRISM2, its multimodal pathology foundation model developed in collaboration with Microsoft researchers. The model demonstrated competitive performance across cancer detection, biomarker prediction, and patient prognosis assessment tasks.
In August 2026, SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop, validate, and commercialize two companion diagnostic programs supporting precision oncology therapies. The agreement combines SOPHiA GENETICS' decentralized testing capabilities and AI-enabled analytical infrastructure with AstraZeneca's therapeutic development programs.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.